Program
nacubactam
Also written as “RO7079901”, “co-administration of cefepime and nacubactam” and “co-administration of aztreonam and nacubactam”.
Its studies are mostly in Intraabdominal Infections · Pyelonephritis · Urinary Tract Infections · Gram-Negative Bacterial Infections · Renal Insufficiency, led by 2 companies.
Drug pageNacubactam: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 40 open or running | phase 1since Nov 21, 2016 | Nov 21, 2016 | none ahead |
| Meiji Seika Pharmaits history only | 30 open or running | phase 3since Mar 2, 2023 | May 7, 2014 | none ahead |
- Named in fosun pharma’s own pipeline as
OP0595 (beta-lactamase inhibitor)
, phase 3, as of Sep 21, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2016Named nacubactamINNProposed as its International Nonproprietary Name in WHO's List 115 · before, RO7079901, OP0595
- Nov 21, 2016First studies: 2 phase 1 studiesFirst studyNCT02972255, NCT02975388
- May 31, 2017Phase 1 study in Urinary Tract InfectionsNCT03174795 · 20 enrolled · United States, Hungary, Latvia and more
- Jun 7, 2017Phase 1 study in Gram-Negative Bacterial InfectionsNCT03182504 · 21 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03182504Gram-Negative Bacterial Infections · United States | 1 | Completed | Aug 10, 2017 | 21 |
| NCT03174795Urinary Tract Infections · United States, Hungary, Latvia and more | 1 | Completed | Dec 4, 2017 | 20 |
| NCT02975388Renal Insufficiency · United States | 1 | Completed | Jul 6, 2017 | 29 |
| NCT02972255Healthy Volunteers · United States | 1 | Completed | Mar 24, 2017 | 46 |
How it is read
Names in the registry
- “RO7079901”, 3 entries
- “co-administration of cefepime and nacubactam”, 2 entries
- “co-administration of aztreonam and nacubactam”, 2 entries
- “nacubactam”, 1 entry
- “OP0595”, 1 entry
Conditions, from the studies’ own filings
- Intraabdominal Infections, 1 study
- Pyelonephritis, 1 study
- Urinary Tract Infections, 1 study
- Gram-Negative Bacterial Infections, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.